ARTICLE | Finance
Seeking Harbour
Why Harbour BioMed acquired mAb licensing play Harbour Antibodies
December 31, 2016 12:34 AM UTC
The scarcity value of the bispecific HCab transgenic mouse technology developed by Harbour Antibodies B.V. - coupled with an established network of partners and licensing revenue - were the drivers behind new Chinese immuno-oncology play Harbour BioMed’s acquisition of the mAb platform company.
On Dec. 19, Harbour BioMed raised $50 million in a series A round that included Chinese investors Advantech Capital and Legend Capital, along with Harbour BioMed founders. In parallel, Harbour BioMed acquired Harbour Antibodies for an undisclosed amount of cash and stock...